Our Technology
SOMaiPRO®
SOMaiPRO® is a Pioneer AI-based Drug Discovery Platform, with a demonstrated high clinical predictivity. Uniquely positioned over any other AI platform for drug discovery due to high predictive clinical value.
Our SOMaiPRO® Technology Platform is based on a proprietary algorithm that matches molecular fields of molecules to discover structure-unrelated analogs. The algorithm is applied to a well characterized library of small molecules already tested in humans.
SOMaiPRO® is best suited, then other AI platforms that needs big data to work with, when applied to clinical indications that have limited or nonbiological information on the disease pathology like rare disorders or idiopathic diseases.
Two of our AI-identified programs have already generated positive Phase 2a clinical results, providing a strong proof-of-concept for our technology in real-world development. All our preclinical programs and early-stage discovery projects are originated directly from our proprietary platform.
Our SOMaiPRO® Technology Platform is based on a proprietary algorithm that matches molecular fields of molecules to discover structure-unrelated analogs. The algorithm is applied to a well characterized library of small molecules already tested in humans.
SOMaiPRO® is best suited, then other AI platforms that needs big data to work with, when applied to clinical indications that have limited or nonbiological information on the disease pathology like rare disorders or idiopathic diseases.
Two of our AI-identified programs have already generated positive Phase 2a clinical results, providing a strong proof-of-concept for our technology in real-world development. All our preclinical programs and early-stage discovery projects are originated directly from our proprietary platform.